Comments Regarding FDA Diversity Action Plans to Improve Enrollment of Participants From Underrepresented Populations in Clinical Studies Share page: Docket Number: FDA–2021–D–0789 Download Document Issues: OTC Medicines Dietary Supplements Consumer Medical Devices Other Issues Research Related Posts Press Releases and Statements CHPA Congratulates Rep. Guthrie on Being Named House E&C Chairman Dec 9, 2024 Comments Comments Regarding Provisions Pertaining to Preventing Access to U.S. Sensitive Personal Data and Government-Related Data Nov 28, 2024 Press Releases and Statements CHPA Responds to Nomination of Dr. Marty Makary for FDA Commissioner Nov 25, 2024